Bimekizumab 3-year Efficacy in High-Impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3/3b Trials. J of Skin. 2024;8(1):s304. doi:10.25251/skin.8.supp.304